primary antibodies to alk1  (R&D Systems)

Journal: Frontiers in Cellular Neuroscience

Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

doi: 10.3389/fncel.2018.00525

Figure Lengend Snippet: mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).

Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

Techniques: Expressing

Journal: Frontiers in Cellular Neuroscience

Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

doi: 10.3389/fncel.2018.00525

Figure Lengend Snippet: Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).

Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

Techniques: Expressing, Staining, Fluorescence, Western Blot, In Vitro

Journal: Oncotarget

Article Title: BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration

doi: 10.18632/oncotarget.11182

Figure Lengend Snippet: A. qRT-PCR analysis of P17 retinas from pups subjected to OIR revealed the expression of transcripts corresponding to components of the canonical BMP9 signaling ( n = 4 control mice and 4 OIR mice). B. Alk1 immunofluorescence staining of OIR retinas at P17 shows specific expression of Alk1 in blood vessels. Arrowheads show vascular tufts. Scale Bar: 20 μm. C. BMP9 ELISA of plasma from mice subjected to OIR collected at P12 (after vaso-obliteration) ( n = 3 control and n = 3 OIR) and P17 (neovascularization phase) ( n = 3 control and n = 4 OIR). D. qRT-PCR of choroid-sclera complexes subjected to laser-CNV of genes involved in BMP9 signaling ( n = 4 mice per group). All histograms represent mean ± standard error of the mean. * P < 0.05.

Article Snippet: Staining with either FITC-labeled isolectin GS IB4 (Life technologies corporation), rhodamine phalloidin (Cedarlane Laboratories) or goat anti-mouse Alk1 primary (R&D systems) and anti-goat secondary (Life technologies) antibodies were performed on whole and/or sectioned retinas/choroids.

Techniques: Quantitative RT-PCR, Expressing, Control, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Journal: Oncotarget

Article Title: BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration

doi: 10.18632/oncotarget.11182

Figure Lengend Snippet: A. IsoB4 staining of P17 retinas from Alk1-flox and Cdh5Cre-Alk1 flox mice subjected to OIR. Injections of tamoxifen were performed at P12, at the onset of neovascularization. Scale bar: 500 μm. B. High magnification of the retinal vasculature shown enlarged vessels accompanied by neovascularization following deletion of Alk1. Scale bar: 50 μm. C. Quantification of neovascular and vaso-obliterated areas in P16 retinas subjected to OIR using ImageJ/Swift ( n = 4 Alk1 fl/fl, n = 4 Cdh5CreERT2-Alk1f/f).

Article Snippet: Staining with either FITC-labeled isolectin GS IB4 (Life technologies corporation), rhodamine phalloidin (Cedarlane Laboratories) or goat anti-mouse Alk1 primary (R&D systems) and anti-goat secondary (Life technologies) antibodies were performed on whole and/or sectioned retinas/choroids.

Techniques: Staining